RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE Russian patent published in 2023 - IPC C12N15/86 C12N7/00 A61K39/215 

FIELD: medicine; biotechnology and virology.

SUBSTANCE: method of obtaining a recombinant influenza virus intended for the prevention of COVID-19 and influenza is described. The method is as follows: using a heterologous fragment containing, but not limited to, immunodominant and signal sequences of SEQ ID NO 1 and SEQ ID NO 2 borrowed from the N protein of the SARS-CoV-2 virus as part of the reading frame of the NS1 truncated protein of the influenza virus. The following is presented: a recombinant influenza virus obtained by this method, which is an influenza A virus with a NS1 protein truncated to 124 amino acids, containing the sequences of SEQ ID NO 1 and SEQ ID NO 2; recombinant influenza virus A/Guangdong/NS124_N (H1N1pdm09), family Orthomyxoviridae, genus Influenza Virus A, obtained by this method, deposited in the State collection of viruses under No. 2981; recombinant virus A/Cambodia/NS124_N (H3N2), family Orthomyxoviridae, genus Influenza Virus A, obtained by the above method, deposited in the State Collection of Viruses under No. 2982. A method of the prevention of COVID-19 and influenza is described, characterized by immunization of subjects with any of the presented recombinant influenza viruses by intranasal administration. The specified technical result is achieved due to the fact that the method for obtaining a recombinant influenza virus consists in using an influenza virus encoding a heterologous fragment containing, but not limited to, the sequences SEQ ID NO 1 and SEQ ID NO 2 borrowed from the N protein of the SARS-CoV-2 virus, which provide a higher level of reproduction of the recombinant virus in the main production substrates, more active expression of the heterologous transgene, and higher immunogenicity compared to similar recombinant viruses that do not contain these sequences.

EFFECT: obtaining highly productive genetically stable recombinant viral influenzas based on an influenza vector expressing a protein fragment of the N virus SARS-CoV-2, which in the mode of intranasal administration induce a pronounced post-vaccination N-specific humoral and T-cell immune response and provide cross-specific protection against infections with the SARS-CoV-2 virus and influenza.

7 cl, 10 dwg, 4 tbl, 7 ex